-

Karen L. Ling joins Galderma’s Advisory Committee

ZUG, Switzerland--(BUSINESS WIRE)--Galderma, the world’s largest independent dermatology company, announced today that Karen L. Ling will join its Advisory Committee, effective March 1, 2022.

Karen Ling has a tremendous track record in executive roles at AIG, Allergan, Merck and Wyeth, guiding compensation, culture and program strategies that greatly improved shareholder relations and attracted and retained competitive talent. She is an accomplished global human resources executive with more than 25 years of pharmaceutical industry experience.

Ms. Ling recently retired from her role as Executive Vice President and Chief Human Resources Officer of American International Group, Inc. (AIG). In this role, she oversaw all aspects of human capital management, including talent development, talent acquisition, compensation and benefits, and diversity, equity and inclusion. At Allergan, as Executive Vice President and Chief Human Resources Officer, she unified multiple, successive acquisitions. She was also instrumental in various innovative compensation programs for the executive leadership team, focused on increasing shareholder value.

 

“I am very pleased to welcome Ms. Ling to Galderma. She
brings to Galderma’s Advisory Committee her extensive
expertise in the area of human resources management, having
led the human capital function at major multinational
companies. She also has wide experience in mergers and
acquisitions – leading seamless integrations and unifying
multiple acquisitions under a shared mission and brand.”

 

THOMAS EBELING

CHAIRMAN ADVISORY COMMITTEE, GALDERMA

 

Ms. Ling currently sits on the Board of Directors and Compensation Committee of iRhythm Technologies (NASDAQ: IRTC) and also sits on the Board of Directors and is Chair of the Compensation Committee of TherapeuticsMD (NASDAQ: TXMD). In addition, she sits on the Board of two non-profit organizations, ExpandED and the JED Foundation. Ms. Ling holds a Juris Doctor from the Boston University School of Law and earned her undergraduate degree from Yale University.

 

“We are thrilled that Karen Ling has decided to join us. Karen has
been a strategic advisor to several Boards of Directors and has
been a member of the executive leadership teams of a number of
global corporations. Karen also has great experience in building
strong performance-based and inclusive organizational cultures.
This appointment will certainly strengthen our Advisory
Committee and also shows our commitment to diversity at
Galderma.”

 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER, GALDERMA

 

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Contacts

Media contact

Christian Marcoux
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Galderma


Release Versions

Contacts

Media contact

Christian Marcoux
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Social Media Profiles
More News From Galderma

New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Dermat...

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama. CPUO is an underdiagnosed condition defined as itch lastin...

Galderma Welcomes Increased Equity Investment From L’Oréal

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise t...
Back to Newsroom